PFIZER INC — Director's Dealing 2022

Jan 10, 2022

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: PFIZER INC (PFE)
CIK: 0000078003
Period of Report: 2022-01-01

Reporting Person: McDermott Michael (Executive Vice President)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	66186.0000	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Appreciation Rights	$22.8900	2023-02-25	Common Stock (14178.0000)		Direct
Stock Appreciation Rights	$25.6000	2022-02-26	Common Stock (12340.0000)		Direct
Stock Appreciation Rights	$27.3400	2022-02-23	Common Stock (14952.0000)		Direct
Stock Appreciation Rights	$27.3400	2024-02-23	Common Stock (12412.0000)		Direct
Stock Appreciation Rights	$30.1700	2023-02-22	Common Stock (13307.0000)		Direct
Stock Appreciation Rights	$30.1700	2025-02-22	Common Stock (11125.0000)		Direct
Stock Appreciation Rights	$31.3100	2025-02-27	Common Stock (48419.0000)		Direct
Stock Appreciation Rights	$31.3100	2027-02-27	Common Stock (41485.0000)		Direct
Stock Appreciation Rights	$33.8200	2026-02-25	Common Stock (37925.0000)		Direct
Stock Appreciation Rights	$33.8200	2028-02-25	Common Stock (32769.0000)		Direct
Stock Appreciation Rights	$38.7100	2024-02-28	Common Stock (18999.0000)		Direct
Stock Appreciation Rights	$38.7100	2026-02-28	Common Stock (16011.0000)		Direct

Footnotes

F1: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

F2: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.